[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cancer-gi\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cancer-gi":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,56,84],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":55},"100590209","postoperative-electrical-muscle-stimulation-two-100590209",false,"NCT06964438","Postoperative Electrical Muscle Stimulation Two","A Three-Arm Randomised Controlled Trial to Establish Effectiveness of NMES With or Without Protein Supplementation to Preserve Muscle Mass and Strength and Improve Functional Outcomes After Abdominal Surgery for GI Cancer","POEMS2","Inclusion Criteria:\n\n* Adult patients (age 18 or over at the time of diagnosis made at MDT (multi-disciplinary team meeting)\n* MDT outcome of colorectal or gastric cancer or non-invasive neoplasia (tissue-proven, or radiologically diagnosed and clinically suspected) with the intention to treat with curative abdominal surgery\n* Agreed management plan for open or minimally invasive (laparoscopic or robot assisted) segmental abdominal (colonic or gastric) resection at the Royal Derby Hospital\n* Sufficient mobility and fitness to complete normal ERAS (enhanced recovery after surgery) protocols following surgery\n* Basic conversational spoken English language\n* Ability to give informed consent\n\nExclusion Criteria:\n\n* Upper GI (gastrointestinal) cancer requiring thoracotomy\u002Fthoracoscopy\n* Pre-existing neuromuscular disease (including Parkinsons disease)\n* Pacemaker, implantable cardiac defibrillator or other implanted nerve stimulator device\n* Metal prostheses or other metal-work in either upper legs (hip\u002Fknee\u002Ffemur)\n* Dementia or other cognitive problem or language barrier causing an inability to follow instructions and operate NMES machine\n* Inability to give informed consent\n* Disability preventing completion of ERAS after surgery (requiring Zimmer frame\u002Fwheeled frame\u002Fwheelchair to mobilise or bed-bound)\n* Peripheral vascular disease\n* Epilepsy\n* Pre-existing diagnosis of chronic kidney disease or estimated glomerular filtration rate \\\u003C60 on screening visit\n* Pre-existing diagnosis of liver disease\n* Intubation or intensive care admission during study period (between day 0-5 post-op); (surgical high dependency unit patients will be included)\n* Return to theatre for surgical complication within first 5-days post operation\n* History of rhabdomyolysis\n* Pregnancy\n* Deep vein thrombosis within past 6-months\n* Allergy to whey protein\n* Patient refusal of whey protein products on grounds of dietary requirements or intolerance\n* Participating in another clinical trial concurrently or within the last 6 months\n* Known infection with blood borne virus","ALL","18 Years",{"count":20,"type":21},45,"ESTIMATED","INTERVENTIONAL",[24],"NA","Undesirable loss of skeletal muscle mass (atrophy) is a common feature of many diseases as well as ageing, bed rest and physical inactivity. Losing muscle can lead to a reduction in one's ability to perform physical activities, and reduce independence and overall health. Muscle mass loss occurs very quickly (i.e., within a few days) after surgery.\n\nThe investigators previous work has shown that neuromuscular electrical stimulation (NMES) of the thigh muscles on one side of the body can help maintain muscle mass and strength on the stimulated side after surgery. Since then, additional work has been carried out to find the most effective form of stimulation to build muscle.\n\nThe current study aims to use this refined stimulation protocol in a clinical trial on the wards after major abdominal surgery. The intervention will involve delivering stimulation to both thighs in the few days after surgery, so that the investigators can assess whether this stimulation can preserve muscle mass and strength, and also, patients' ability to perform physical activities after surgery. In addition, the study will aim to find out whether any benefit provided by electrical stimulation can be increased further by taking a protein supplement at the same time.",[27,28,29,30],"Surgery","Colorectal Cancer","Muscle Atrophy","Cancer Gi",[32,33,34,35,36,37,38,39,40,41,42],"electrical stimulation","neuromuscular electrical stimulation","NMES","rehabilitation","general surgery","colorectal surgery","laparotomy","laparoscopy","postoperative recovery","gastrointestinal cancer","gastrointestinal surgery","RECRUITING","2026-06-10",{"date":46,"type":47},"2026-06-15","ACTUAL",{"date":49,"type":47},"2025-06-05",{"date":51,"type":21},"2027-03-01",{"name":53,"class":54},"University of Nottingham","OTHER",1,{"id":57,"slug":58,"hasResults":11,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":62,"eligibilityCriteria":63,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":64,"enrollmentInfo":65,"targetDuration":4,"studyType":22,"phases":67,"briefSummary":68,"conditions":69,"keywords":70,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":83},"100515670","prophylactic-eus-guided-gastroenterostomy-in-advanced-periampullary-cancers-100515670","NCT05994521","Prophylactic EUS-guided Gastroenterostomy in Advanced Periampullary Cancers","Prophylactic EUS-guided Gastroenterostomy in Advanced Periampullary Cancers: a Multicenter Randomized Controlled Trial","INTERCEPT","Inclusion Criteria (all of the following):\n\n1. Radiological diagnosis of a periampullary cancer that is precluded from upfront surgical resection of curative intent due to advanced tumor stage. These include locally advanced or metastatic cancers of the pancreatic head, distal bile duct, duodenum, or ampulla. cancers.\n2. Elevated liver function tests requiring ERCP without evidence of MGOO of significant gastroparesis (see exclusion criterion #3 and #4)\n3. ECOG 0 or 1\n4. ASA\\\u003C4\n5. Provision of informed consent\n\nExclusion Criteria (any of the following):\n\n1. Patient with clinical and radiological evidence of malignant gastric outlet obstruction defined as Gastric Outlet Obstruction Scoring System (GOOSS) of \\\u003C 3 with radiological and\u002For endoscopic evidence of a mechanical obstruction from a gastric or duodenal stricture. GOOSS is a validated tool for assessing MGOO and is scored based on the diet tolerated by the patient: 0 for no oral intake, 1 for liquids only, 2 for soft diet, and 3 for low residue or full diet.\n2. Gastroparesis with a Gastroparesis Cardinal Symptom Index (GCSI) of \\>2. Gastroparesis is defined as having symptoms of MGOO without radiological and\u002For endoscopic evidence of mechanical obstruction.\n3. Uncorrectable coagulopathy and\u002For thrombocytopenia\n4. Age \\\u003C 18 or ≥ 85\n5. Evidence of peritoneal carcinomatosisAscites\n6. Liver metastasis \\> 30% of the liver volume\n7. Portal hypertension with gastroesophageal varices and\u002For ascites\n8. Surgically altered upper gastrointestinal anatomy","85 Years",{"count":66,"type":21},110,[24],"The goal of this randomized controlled trial is to investigate the effectiveness and safety of Prophylactic EUS-gastroenterostomy (ProEUS-GE) as a preventative approach for malignant gastric outlet obstruction (MGOO) in men and women aged 18 years or older diagnosed with periampullary cancer.\n\nThe main question this study aims to answer is can ProEUS-GE effectively prevent the occurrence of MGOO in patients with periampullary cancer?\n\nPatients will be randomly assigned to one of two groups: Group 1 (ERCP alone) or Group 2 (ERCP + ProEUS-GE). The study will compare the outcomes between these groups to determine the effectiveness of ProEUS-GE in preventing MGOO.\n\nResearchers will compare Group 1 (ERCP alone) with Group 2 (ERCP + ProEUS-GE) to see if the addition of ProEUS-GE leads to a reduced occurrence of MGOO in patients with periampullary cancer.\n\nThe primary endpoint is the rate of malignant gastric outlet obstruction.",[30],[71,72,73],"periampullary cancer","ERCP","EUS-Guided gastroeterostomy","2024-09-27",{"date":76,"type":47},"2024-10-01",{"date":78,"type":47},"2024-04-09",{"date":80,"type":21},"2027-08",{"name":82,"class":54},"McGill University Health Centre\u002FResearch Institute of the McGill University Health Centre",5,{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":88,"acronym":4,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":90,"targetDuration":4,"studyType":22,"phases":92,"briefSummary":93,"conditions":94,"keywords":4,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":55},"100560789","eye-gaze-technology-for-endoscopic-inspection-of-the-gastrointestinal-tract-100560789","NCT06581718","Eye Gaze Technology for Endoscopic Inspection of the Gastrointestinal Tract","Inclusion Criteria:\n\n* Routine UGI endoscopic indications\n\nExclusion Criteria:\n\n* Varices\n* \\\u003C18\n* GI haemorrhage\n* PS \\> 2",{"count":91,"type":21},10,[24],"Robotic controlled endoscopy of GI tract.",[30],"2024-08-30",{"date":97,"type":47},"2024-09-03",{"date":99,"type":47},"2024-05-01",{"date":101,"type":21},"2024-09",{"name":103,"class":54},"Imperial College London"]